As one of the major SCFAs, BA supplementation not only reduced plasma TG, TC, and glucose levels with an increase in HDL-C level but also modulated immune response to suppress the inflammation, eventually improving NASH and atherosclerosis in HFHC diet-fed LDLR-/- hamsters showing severe CHL and demonstrating that BA could be a potential therapeutic approach to treat CHL disease. The gene discussed is LDLR; the disease is metabolic dysfunction-associated steatohepatitis.